Physician profile
Karen E Moore
NPI 1487924650
$4,545.93
in general payments reported to CMS, 2019-2025
24 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $755 · 2023: $798 · 2024: $771 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $879.42 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $447.62 | 2021-2023 | |
| Madrigal Pharmaceuticals | $392.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $375.66 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $361.44 | 2021-2023 | Xarelto |
| Gilead Sciences, INC. | $308.39 | 2022-2025 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $251.21 | 2022-2023 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $204.05 | 2024-2025 | Eohilia, Entyvio |
| Regeneron Healthcare Solutions, INC. | $184.45 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $177.58 | 2024-2025 | Sucraid, Sucraid |
| Astrazeneca Pharmaceuticals LP | $146.62 | 2022-2025 | Imfinzi, Tezspire |
| Sobi, INC | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $112.50 | 2023 | Keytruda |
| Genzyme Corporation | $109.43 | 2024-2025 | |
| Ardelyx, INC. | $106.55 | 2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $88.08 | 2024-2025 | Stelara, Tremfya |
| Pharmacosmos Therapeutics INC. | $85.94 | 2023 | Monoferric |
| Ironwood Pharmaceuticals, INC | $46.29 | 2024 | |
| Amgen INC. | $39.52 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $32.29 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $19.57 | 2025 | Sutab, Suflave |
| Abbott Laboratories | $19.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.54 | 2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $16.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.